Amina B S, Anshul S, Sharan T K, Anusha R S, Lewis Shirley, Umesh V, Priyanka A, Tarun G
Department of Radiotherapy and Oncology, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka India.
Indian J Otolaryngol Head Neck Surg. 2022 Dec;74(Suppl 3):6146-6150. doi: 10.1007/s12070-021-02810-7. Epub 2021 Aug 17.
To report the outcomes of patients with head and neck squamous cell cancers (HNSCC) who received radiotherapy as a part of their first line treatment. All patients treated with radiotherapy for HNSCC between 2013 and 2017 were retrospectively identified from the department records. Patients with follow-up of less than 3 months following primary treatment were excluded. The demographic, disease and outcome details were retrieved from the patients' hospital records. The disease free survival (DFS) was estimated with Kaplan-Meier analysis, and effect of different variables on DFS were compared using log-rank test. The late toxicities of treatment were also recorded and reported. A total of 311 patients were found to be eligible. Most patients were males (82%), and oral cavity cancers predominated (45.3%). 237 patients (76.2%) had locally advanced disease at presentation. Radiotherapy was used as definitive treatment for 152 patients (48.9%). At a median follow up of 14.8 months (range: 3-85.2 months), the estimated Disease-Free Survival (DFS) was 52.7 months (95%CI: 37.7-67.7 months). Locally advanced disease correlated with a significantly lower median DFS (61.2 vs. 32.8 months; = 0.01), but other factors, including gender, use of concurrent chemotherapy and adjuvant vs definitive radiotherapy appeared to have no statistical association with DFS. 181 (58.2%) patients had chronic RT-related toxicities at last follow-up, but most were generally mild, most frequently subcutaneous fibrosis (48.6%, which occurred significantly more frequently in patients receiving adjuvant RT following surgery- 40.8% versus 57.2%; = 0.03) and xerostomia (32.4%). Radiation induced osteoradionecrosis was rare, occurring in only three (1%).Most HNSCC patients present with locally advanced disease, where disease control remains poor. Though there is substantial toxicity following treatment, the risk of severe toxicities with modern radiotherapy is low.
报告接受放射治疗作为一线治疗一部分的头颈部鳞状细胞癌(HNSCC)患者的治疗结果。从科室记录中回顾性识别出2013年至2017年间所有接受HNSCC放射治疗的患者。排除初次治疗后随访时间少于3个月的患者。从患者的医院记录中获取人口统计学、疾病和结局细节。采用Kaplan-Meier分析估计无病生存期(DFS),并使用对数秩检验比较不同变量对DFS的影响。还记录并报告了治疗的晚期毒性。共发现311例患者符合条件。大多数患者为男性(82%),以口腔癌为主(45.3%)。237例患者(76.2%)初诊时为局部晚期疾病。152例患者(48.9%)将放射治疗作为根治性治疗。中位随访14.8个月(范围:3 - 85.2个月),估计无病生存期(DFS)为52.7个月(95%CI:37.7 - 67.7个月)。局部晚期疾病与显著更低的中位DFS相关(61.2对32.8个月;P = 0.01),但其他因素,包括性别、同步化疗的使用以及辅助放疗与根治性放疗,似乎与DFS无统计学关联。181例(58.2%)患者在最后一次随访时有慢性放疗相关毒性,但大多数一般较轻,最常见的是皮下纤维化(48.6%,在术后接受辅助放疗的患者中发生频率显著更高 - 40.8%对57.2%;P = 0.03)和口干(32.4%)。放射性骨坏死很少见,仅3例(1%)发生。大多数HNSCC患者初诊时为局部晚期疾病,疾病控制仍然较差。尽管治疗后有大量毒性,但现代放疗导致严重毒性的风险较低。